RHHBY Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -- compared to Roche Holding AG's net margin of 8.69%. Roche Holding AG's return on equity of 28.65% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

Roche Holding AG has a consensus price target of $58.80, signalling downside risk potential of -0.64%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $59.91 which suggests that it could fall by -0.64%. Given that Roche Holding AG has more downside risk than Bristol Myers Squibb Co., analysts believe Bristol Myers Squibb Co. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.440, which suggesting that the stock is 56.044% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.296%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.35%. Bristol Myers Squibb Co. offers a yield of 4.13% to investors and pays a quarterly dividend of $0.63 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Roche Holding AG's net income of -- is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Roche Holding AG's price-to-earnings ratio is 24.63x while Bristol Myers Squibb Co.'s PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.13x versus 2.55x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Roche Holding AG's net margin of 34.4%. Roche Holding AG's return on equity of 28.65% beat Eli Lilly & Co.'s return on equity of 104.39%.

Roche Holding AG has a consensus price target of $58.80, signalling downside risk potential of -0.64%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,206.07 which suggests that it could grow by 17.87%. Given that Eli Lilly & Co. has higher upside potential than Roche Holding AG, analysts believe Eli Lilly & Co. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.440, which suggesting that the stock is 56.044% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.35%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Roche Holding AG's net income of -- is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Roche Holding AG's price-to-earnings ratio is 24.63x while Eli Lilly & Co.'s PE ratio is 45.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.13x versus 14.30x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Roche Holding AG's net margin of 18.06%. Roche Holding AG's return on equity of 28.65% beat Merck & Co., Inc.'s return on equity of 39.63%.

Roche Holding AG has a consensus price target of $58.80, signalling downside risk potential of -0.64%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.48%. Given that Merck & Co., Inc. has higher upside potential than Roche Holding AG, analysts believe Merck & Co., Inc. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.440, which suggesting that the stock is 56.044% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.35%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Roche Holding AG's net income of -- is lower than Merck & Co., Inc.'s net income of $3B. Notably, Roche Holding AG's price-to-earnings ratio is 24.63x while Merck & Co., Inc.'s PE ratio is 16.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.13x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 18.03%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 32.47%.

Roche Holding AG has a consensus price target of $58.80, signalling downside risk potential of -0.64%. On the other hand Novartis AG has an analysts' consensus of $139.80 which suggests that it could fall by -14.71%. Given that Novartis AG has more downside risk than Roche Holding AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.440, which suggesting that the stock is 56.044% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.176%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.35%. Novartis AG offers a yield of 2.44% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Novartis AG pays out 42.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.3B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.4B. Notably, Roche Holding AG's price-to-earnings ratio is 24.63x while Novartis AG's PE ratio is 22.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.13x versus 5.85x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.